Research led by Friedrich-Alexander-Universität Erlangen–Nürnberg provides evidence that teclistamab may offer therapeutic ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...
China Medical University leads a multi-institution team reporting that MTAP deficiency suppresses cytosolic nucleic acid ...
Approved KRAS inhibitors Lumakras and Krazati may soon face more competition as second-generation G12C inhibitors and other KRAS approaches advance.
First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating ...
A new human liver organoid microarray developed by Cincinnati Children’s and Roche recreates immune-driven liver injury in ...
Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, ...
While some AI-designed drugs have made it to clinical trials, none of them have been approved. Why has it been harder than ...
Researchers at Cincinnati Children's Hospital Medical Center in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that could help predict which drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback